Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study

Tüylü, Tuğba Başoğlu; Sarı, İ̇smail; Solmaz, Dilek; Kozacı, Didem; Akar, Servet; Günay, Necati; Önen, Fatoş; Akkoç, Nurullah

doi:10.6061/clinics/2014(10)07

Cited by 20 publications

(17 citation statements)

References 34 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings were seen in two other cohorts of Swedish [50] and Brazilian AS patients [64]. Yet, other studies showed no differences or even demonstrated elevated levels of sclerostin comparing between AS patients and controls [46, 65, 66]. …”

Section: Markers Of Radiographic Severity and Progression (Table 3)supporting

confidence: 85%

“…AS patients with syndesmophytes have been shown to have significantly higher levels of fetuin-A compared with patients without syndesmophytes and controls [65]. However, fetuin-A levels were not different between patients without syndesmophytes and controls, and on regression analysis, fetuin-A was an independent, significant predictor of syndesmophyte formation.…”

Section: Markers Of Radiographic Severity and Progression (Table 3)mentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis

Reveille

2015

Clin Rheumatol

View full text Add to dashboard Cite

With the growing awareness of the impact of chronic back pain and axial spondyloarthritis and recent breakthroughs in genetics and the development of novel treatments which may impact best on early disease, the need for markers that can facilitate early diagnosis and profiling those individuals at the highest risk for a bad outcome has never been greater. The genetic basis of ankylosing spondylitis has been considerably advanced, and HLA-B27 testing has a role in the diagnosis. Knowledge is still incomplete of the rest of the genetic contribution to disease susceptibility, and it is likely premature to use extensive genetic testing (other than HLA-B27) for diagnosis. Serum and plasma biomarkers have been examined extensively in assessing disease activity, treatment response, and as predictors or radiographic severity. For assessing disease activity, other than C-reactive protein and erythrocyte sedimentation rate, the most work has been in examining cytokines (particularly interleukin 17 and 23), matrix metalloproteinase (MMP) markers (particularly MMP3). For assessing those at the highest risk for radiographic progression, biomarkers of bony metabolism, cartilage and connective tissue degradation products, and adipokines have been most extensively assessed. The problem is that no individual biomarkers has been reproducibly shown to assess disease activity or predict outcome, and this area still remains an unmet need, of relevance to industry stakeholders, to regulatory bodies, to the healthcare system, to academic investigators, and finally to patients and providers.

show abstract

Section: Markers Of Radiographic Severity and Progression (Table 3)supporting

confidence: 85%

Section: Markers Of Radiographic Severity and Progression (Table 3)mentioning

confidence: 99%

Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis

Reveille

2015

Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…[3] However, there are contradictory results regarding the association of SOST in SpA patients. [21–23] In the present study, no difference between the 2 groups was noted. This may attribute to small sample size of patients and short-term duration of study.…”

Section: Discussioncontrasting

confidence: 54%

Increased serum levels of MIC1/GDF15 correlated with bone erosion in spondyloarthritis

et al. 2018

View full text Add to dashboard Cite

Introduction:To assess the association between growth differentiation factor-15 (GDF15) and radiographic features including bone marrow edema and bone erosion in Spondyloarthritis (SpA).Methods:Patients with SpA (n = 120) receiving treatment in the Guangdong General Hospital, China, between August 2012 and December 2016 were retrospectively included. Serum of patients and healthy controls (n = 30) were collected and GDF15 levels were measured using ELISA. Inflammation was assessed by C-reactive protein (CRP), and magnetic resonance imaging (MRI) of the sacroiliac joint using Spondyloarthritis Research Consortium of Canada score and a method of dichotomy to assess fat metaplasia, bone erosion, and ankylosis. Radiographs of the pelvis were scored using the modified New York (mNY) score.Results:Serum GDF15 levels were higher in SpA patients compared to controls (503.52 ± 222.92 vs. 190.86 ± 104.18 pg/mL, P < .0001). Patients who suffered from bone erosion on MRI had higher levels of GDF15 (525.72 [186.33, 801.62]vs. 428.06 [255.15, 670.98] pg/mL, P = .0375). There was a positive correlation between serum GDF15 and CRP (r = 0.5442, P < .0001). Moreover, GDF15 levels were related to CRP levels (r = 0.5658, P < .0001) in those X-ray scores were III, according to 1984mNY criteria. Receiver operating characteristic (ROC) analysis showed that GDF15 levels above 501.98pg/mL could predict presence of bone erosion on MRI.Conclusion:The present study suggested that serum GDF15 levels are higher in SpA patients than in healthy controls. The GDF15 level was correlated with CRP and may be a surrogate biomarker in bone erosion.

show abstract

“…Sparse data are available regarding serum IL-18, fetuin-A, sICAM-1, and ET-1 in SpA patients, as these markers are mainly considered in AS [ 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome

Przepiera-Będzak

Fischer

Brzosko

2016

IJMS

View full text Add to dashboard Cite

To examine serum interleukin 18 (IL-18), fetuin-A, soluble intercellular adhesion molecule-1 (sICAM-1), and endothelin-1 (ET-1) levels in ankylosing spondylitis (AS), psoriatic arthritis (PsA), and Synovitis Acne Pustulosis Hyperostosis Osteitis syndrome (SAPHO). We studied 81 AS, 76 PsA, and 34 SAPHO patients. We measured serum IL-18, fetuin-A, sICAM-1, ET-1, IL-6, IL-23, vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF). IL-18 levels were higher in AS (p = 0.001), PsA (p = 0.0003), and SAPHO (p = 0.01) than in controls, and were positively correlated with CRP (p = 0.03), VEGF (p = 0.03), and total cholesterol (TC, p = 0.006) in AS and with IL-6 (p = 0.03) in PsA. Serum fetuin-A levels were lower in AS (p = 0.001) and PsA (p = 0.001) than in controls, and negatively correlated with C-reactive protein (CRP) in AS (p = 0.04) and SAPHO (p = 0.03). sICAM-1 positively correlated with CRP (p = 0.01), erythrocyte sedimentation rate (ESR, p = 0.01), and IL-6 (p = 0.008) in AS, and with IL-6 (p = 0.001) in SAPHO. Serum ET-1 levels were lower in AS (p = 0.0005) than in controls. ET-1 positively correlated with ESR (p = 0.04) and Disease Activity Score 28 (DAS28, p = 0.003) in PsA. In spondyloarthritis, markers of endothelial function correlated with disease activity and TC.

show abstract

Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study

Cited by 20 publications

References 34 publications

Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis

Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis

Increased serum levels of MIC1/GDF15 correlated with bone erosion in spondyloarthritis

Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome

Contact Info

Product

Resources

About